Quick Answer
Wave Life Sciences Ltd. reported Total Revenue of $42.73 million for fiscal year 2025.
Wave Life Sciences Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $42.73M -60.5% |
$108.30M -4.4% |
$113.31M +3005.1% |
$3.65M -91.1% |
$40.96M +104.0% |
$20.08M +25.6% |
| Revenue (ASC 606) | $42.73M -60.5% |
$108.30M -4.4% |
$113.31M +3005.1% |
$3.65M -91.1% |
$40.96M +104.0% |
$20.08M +25.6% |
| Net Income | -$204.38M -110.7% |
-$97.01M -68.7% |
-$57.51M +64.5% |
-$161.82M -32.4% |
-$122.25M +18.5% |
-$149.91M +22.6% |
| Diluted EPS | -$1.21 -72.9% |
-$0.70 -29.6% |
-$0.54 +73.7% |
-$2.05 +13.1% |
-$2.36 | — |
| Total Assets | $638.50M +81.3% |
$352.21M +28.1% |
$274.95M +87.8% |
$146.39M -29.3% |
$207.01M -25.9% |
$279.24M -1.8% |
| Cash and Equivalents | $602.07M +99.3% |
$302.08M +50.8% |
$200.35M +126.4% |
$88.50M -41.2% |
$150.56M -18.4% |
$184.50M +25.4% |
| Stockholders Equity | $518.36M +147.4% |
$209.51M +428.7% |
$39.63M +187.9% |
-$45.09M -238.8% |
$32.50M -60.7% |
$82.78M +29.9% |
| R&D Expense | $182.78M +14.5% |
$159.68M +22.8% |
$130.01M +12.2% |
$115.86M -4.9% |
$121.88M -6.9% |
$130.94M -25.4% |
| Operating Income | -$215.38M -95.1% |
-$110.40M -62.4% |
-$68.00M +58.2% |
-$162.72M -28.1% |
-$127.02M +17.2% |
-$153.38M +26.4% |
| Shares Outstanding | 187.66M +22.6% |
153.04M +28.4% |
119.16M +37.1% |
86.92M +45.3% |
59.84M +22.7% |
48.78M +42.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $8.70M | -55.8% | -5.2% |
| Revenue (ASC 606) | June 30, 2025 | $8.70M | -55.8% | -5.2% |
| Net Income | September 30, 2025 | -$53.85M | +12.8% | -6.7% |
| Diluted EPS | September 30, 2025 | -$0.32 | +31.9% | -3.2% |
| Total Assets | September 30, 2025 | $241.38M | -32.7% | -4.3% |
| Cash and Equivalents | September 30, 2025 | $196.22M | -36.9% | -5.9% |
| Stockholders Equity | September 30, 2025 | $124.55M | -12.1% | -10.6% |
| R&D Expense | September 30, 2025 | $45.87M | +11.4% | +5.5% |
| Operating Income | September 30, 2025 | -$56.35M | +11.8% | -6.8% |
| Shares Outstanding | September 30, 2025 | 160.29M | +8.0% | +3.0% |
- Wave Life Sciences Ltd. reported Total Revenue of $42.73 million for fiscal year 2025.
- Wave Life Sciences Ltd. showed a decrease of -60.5% in Total Revenue compared to the prior fiscal year.
- Wave Life Sciences Ltd. reported Revenue (ASC 606) of $42.73 million for fiscal year 2025.
- Wave Life Sciences Ltd. showed a decrease of -60.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Wave Life Sciences Ltd. reported Net Income of -$204.38 million for fiscal year 2025.
- Wave Life Sciences Ltd. showed a decrease of -110.7% in Net Income compared to the prior fiscal year.
- Wave Life Sciences Ltd. reported Diluted EPS of $1.21 per share (loss) for fiscal year 2025.
- Wave Life Sciences Ltd. showed a decrease of -72.9% in Diluted EPS compared to the prior fiscal year.
- Wave Life Sciences Ltd. reported Total Assets of $638.50 million for fiscal year 2025.
- Wave Life Sciences Ltd. showed an increase of +81.3% in Total Assets compared to the prior fiscal year.
- Wave Life Sciences Ltd. reported Cash and Equivalents of $602.07 million for fiscal year 2025.
- Wave Life Sciences Ltd. showed an increase of +99.3% in Cash and Equivalents compared to the prior fiscal year.
- Wave Life Sciences Ltd. reported Stockholders Equity of $518.36 million for fiscal year 2025.
- Wave Life Sciences Ltd. showed an increase of +147.4% in Stockholders Equity compared to the prior fiscal year.
- Wave Life Sciences Ltd. reported R&D Expense of $182.78 million for fiscal year 2025.
- Wave Life Sciences Ltd. showed an increase of +14.5% in R&D Expense compared to the prior fiscal year.
- Wave Life Sciences Ltd. reported Operating Income of -$215.38 million for fiscal year 2025.
- Wave Life Sciences Ltd. showed a decrease of -95.1% in Operating Income compared to the prior fiscal year.
- Wave Life Sciences Ltd. reported Shares Outstanding of 187.66 million shares for fiscal year 2025.
- Wave Life Sciences Ltd. showed an increase of +22.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: